Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up - Should You Buy?

Key Points

• Hikma Pharmaceuticals' stock price gapped up from $22.46 to $25.18 before the market opened on Wednesday.
• The company operates in three segments: Injectables, Generics, and Branded products, focusing on generic injectable products primarily for hospitals.
• Hikma Pharmaceuticals has a debt-to-equity ratio of 0.33 and a quick ratio of 0.72, indicating a manageable level of debt and liquidity for operational needs.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - )'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $22.46, but opened at $25.18. Hikma Pharmaceuticals shares last traded at $25.18, with a volume of 184 shares changing hands.

Hikma Pharmaceuticals Stock Performance

The company has a quick ratio of 0.72, a current ratio of 1.24 and a debt-to-equity ratio of 0.33. The company's fifty day simple moving average is $23.82 and its 200-day simple moving average is $25.96.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.